Key Takeaways
- • Regeneron Pharmaceuticals launched Regeneron Ventures on Monday with a $500 million commitment to deploy over five years, positioning itself among major pharmaceutical peers with dedicated venture capital arms.
- • The venture fund will be led by Jay Markowitz, M.D. (former senior partner at Arch Venture Partners) and Michael Aberman, M.D. (former senior vice president of investor relations and strategy at Regeneron), both of whom bring substantial industry and investing experience.
- • Regeneron Ventures operates with a sector-agnostic investment philosophy, targeting biotech companies across all therapeutic areas and development stages, plus adjacent sectors including medical devices, tools, and enabling technologies.
- • The initiative aligns Regeneron with major pharma competitors—including Sanofi, Eli Lilly, Bristol Myers Squibb, Astellas, and Novartis—that have established venture capital divisions, reflecting industry consolidation around innovation sourcing and ecosystem development.
- • The fund's strategy emphasizes leveraging Regeneron's internal experience and scientific capabilities to identify and support early-stage companies pursuing transformative advances in science and medicine.
Summary
Regeneron Pharmaceuticals formally entered the corporate venture capital space Monday, announcing Regeneron Ventures with a five-year, $500 million investment commitment. The initiative reflects broader consolidation among large pharmaceutical companies establishing in-house venture arms to source innovation, validate emerging technologies, and maintain competitive positioning in rapidly evolving therapeutic areas.
Leadership of the new fund comprises two seasoned executives with complementary backgrounds. Jay Markowitz, M.D., joins as co-leader from Arch Venture Partners, where he served as senior partner and played a founding role in three companies. His earlier tenure at Regeneron (2017-2020) as senior vice president followed 16 years in public capital markets investing, including eight years at T. Rowe Price. Co-leader Michael Aberman, M.D., spent seven years at Regeneron in senior strategy and investor relations roles before leading two biotech companies—Quentis Therapeutics and XenImmune Therapeutics—providing direct operating experience in the biotech sector.
The fund adopts a deliberately broad investment mandate, remaining "agnostic to therapeutic area, technology and stage of development." This expansive scope extends beyond traditional drug development to encompass medical devices, diagnostic tools, and enabling technologies supporting the broader life sciences ecosystem. Leadership characterized the fund's ethos as risk-tolerant and intellectually rigorous: "We tolerate risk and uncertainty. We are open-minded. We doubt and question."
Regeneron's move mirrors strategy deployed by nearly all major pharmaceutical peers. According to HSBC data, leading corporate venture investors in 2023 included Sanofi, Eli Lilly, Bristol Myers Squibb, Astellas, and Novartis. By establishing a dedicated venture arm, Regeneron gains direct visibility into emerging science and technologies, creates optionality for future partnerships or acquisitions, and deepens relationships within the biotech ecosystem—all while leveraging internal scientific expertise and operational knowledge to support portfolio companies.
Leadership of the new fund comprises two seasoned executives with complementary backgrounds. Jay Markowitz, M.D., joins as co-leader from Arch Venture Partners, where he served as senior partner and played a founding role in three companies. His earlier tenure at Regeneron (2017-2020) as senior vice president followed 16 years in public capital markets investing, including eight years at T. Rowe Price. Co-leader Michael Aberman, M.D., spent seven years at Regeneron in senior strategy and investor relations roles before leading two biotech companies—Quentis Therapeutics and XenImmune Therapeutics—providing direct operating experience in the biotech sector.
The fund adopts a deliberately broad investment mandate, remaining "agnostic to therapeutic area, technology and stage of development." This expansive scope extends beyond traditional drug development to encompass medical devices, diagnostic tools, and enabling technologies supporting the broader life sciences ecosystem. Leadership characterized the fund's ethos as risk-tolerant and intellectually rigorous: "We tolerate risk and uncertainty. We are open-minded. We doubt and question."
Regeneron's move mirrors strategy deployed by nearly all major pharmaceutical peers. According to HSBC data, leading corporate venture investors in 2023 included Sanofi, Eli Lilly, Bristol Myers Squibb, Astellas, and Novartis. By establishing a dedicated venture arm, Regeneron gains direct visibility into emerging science and technologies, creates optionality for future partnerships or acquisitions, and deepens relationships within the biotech ecosystem—all while leveraging internal scientific expertise and operational knowledge to support portfolio companies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.